clinical trials for glp-1 obesity meds actively recruiting 2024 was a record year and 2025 is already poised to take over The GLP-1 Revolution: How Next-Generation
Description
Your one stop guide
Roxborough Clinic in Silver Spring, MD, led by Dr
Henney 2024) demonstrated a potentially meaningful reduction in incident pneumonia with GLP-1 RAs compared with dipeptidyl peptidase-4 (DPP-4) inhibitors (hazard ratio [HR] 0.60, 95% confidence interval [CI] 0.580.62
KEY BENEFITS
